Review
Open access
Oct 2026
Reclassification of obstetric antiphospholipid syndrome under the 2023 ACR/EULAR criteria: risk of under-recognition in patients with non-criteria antibodies and clinical implications
Findings support using the 2023 criteria primarily to define homogeneous research cohorts rather than as a stand-alone basis for diagnosis or treatment decisions, and support using the 2023 criteria primarily to define homogeneous research cohorts.
Ting-Wei Sheng, Yu-Qi Tang, Zheng-Wei Tan et al.
· Frontiers in Medicine · 0 citations